Principal Financial Group
PRQR icon

Principal Financial Group’s ProQR Therapeutics PRQR Stock Holding History

Principal Financial Group’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-72,796
Closed -$224K – 2301
2018
Q1 		$224K Sell
72,796
-300
-0.4% -$965 ﹤0.01% 2082
2017
Q4 		$236K Sell
73,096
-8,398
-10% -$30.1K ﹤0.01% 2101
2017
Q3 		$395K Buy
81,494
+5,000
+7% +$26K ﹤0.01% 1967
2017
Q2 		$398K Hold
76,494
– – ﹤0.01% 1995
2017
Q1 		$382K Hold
76,494
– – ﹤0.01% 1965
2016
Q4 		$375K Hold
76,494
– – ﹤0.01% 1973
2016
Q3 		$510K Hold
76,494
– – ﹤0.01% 1856
2016
Q2 		$370K Sell
76,494
-1,800
-2% -$9.26K ﹤0.01% 1892
2016
Q1 		$382K Hold
78,294
– – ﹤0.01% 1886
2015
Q4 		$680K Sell
78,294
-4,956
-6% -$57K ﹤0.01% 1824
2015
Q3 		$1.21M Buy
83,250
+1,610
+2% +$27K ﹤0.01% 1742
2015
Q2 		$1.36M Buy
81,640
+5,840
+8% +$110K ﹤0.01% 1745
2015
Q1 		$1.66M Buy
75,800
+400
+0.5% +$8.26K ﹤0.01% 1689
2014
Q4 		$1.63M Buy
+75,400
New +$1.14M ﹤0.01% 1717

Other funds holding PRQR

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Principal Financial Group's PRQR Position: Q2 2018 in Review

Principal Financial Group sold out of ProQR Therapeutics (PRQR) in Q2 2018, closing a stake of 72,796 shares — an estimated $224K sold.

Principal Financial Group first reported a position in PRQR in Q4 2014 and held it in 14 quarters. The position peaked at $1.66M in Q1 2015. 25 funds tracked by Wall St. Rank hold PRQR as of Q2 2018.

  • Principal Financial Group reported no remaining ProQR Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Principal Financial Group sold 72,796 ProQR Therapeutics shares in Q2 2018, an estimated $224K.
  • Principal Financial Group first reported a position in ProQR Therapeutics in Q4 2014 and held it in 14 quarters.
  • Principal Financial Group's ProQR Therapeutics position peaked at $1.66M in Q1 2015.
  • 25 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2018.

Based on Principal Financial Group's 13F filing for Q2 2018, filed 13 Aug 2018.